Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy - PubMed (original) (raw)
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
Marieke Griffioen et al. Haematologica. 2009 Sep.
Abstract
The aim of adoptive T-cell therapy of cancer is to selectively confer immunity against tumor cells. Autoimmune side effects, however, remain a risk, emphasizing the relevance of a suicide mechanism allowing in vivo elimination of infused T cells. We investigated the use of human CD20 as suicide gene in T-lymphocytes. Potential effects of forced CD20 expression on T-cell function were investigated by comparing CD20- and mock-transduced cytomegalovirus (CMV) specific T cells for cytolysis, cytokine release and proliferation. The use of CD20 as suicide gene was investigated in CMV specific T cells and in T cells genetically modified with an antigen specific T-cell receptor. No effect of CD20 on T-cell function was observed. CD20-transduced T cells with and without co-transferred T-cell receptor were efficiently eliminated by complement dependent cytotoxicity induced by therapeutic anti-CD20 antibody rituximab. The data support the broad value of CD20 as safety switch in adoptive T-cell therapy.
Figures
Figure 1.
Delivery of human CD20 by retroviral vectors. Jurkat-T cells were transduced with MP71-CD20-IRES-NGFR and LZRS-CD20-IRES-NGFR retroviral vectors. Indicated are the mean fluorescence intensities after staining with PE-labeled anti-CD20 and APC-labeled anti-NGFR antibodies.
Figure 2.
Human CD20 as suicide gene in cytomegalovirus specific T cells. CD20- and mock-transduced T-cell clones specific for pp50-VTE, IE1-ELR and IE1-QIK were isolated and compared for functional activity upon stimulation with autologous EBV-LCL pulsed with titrated CMV peptides. T cells specific for pp50-VTE are shown as representative examples. (A) Flow cytometric analysis after staining with CMV tetramers and antibodies against CD20 and NGFR. (B) T cells were tested for cytolytic activity in 51Cr-release assays at E:T ratios of 10:1 (upper), specific release of IFN-γ in ELISA (middle) and proliferative capacity by flow cytometry (lower). (C) CD20- and mock-transduced CMV specific T-cell clones were compared for RTX-induced CDC. T cells were treated with RTX and BRC or heat inactivated HS for 1 h at 37°C and analyzed for percentages of viable (PI−) cells relative to cultures incubated in medium with heat inactivated HS without RTX (100%) (upper). After CDC, T cells were washed and tested for cytolytic activity against peptide-pulsed autologous EBV-LCL in 51Cr-release assays at E:T ratios of 10:1 as counted prior to CDC (lower).
Figure 3.
Human CD20 as suicide gene in TCR gene transfer. (A) CD20-transduced peptide-stimulated CD8+ cells from a healthy donor were analyzed by flow cytometry before (upper) as well as one week after (lower) isolation by magnetic beads and subsequent in vitro expansion. (B) CD20-isolated T cells were restimulated and transduced with the HA-2 TCR. CD20+ HA-2-tetramer+ T cells were sorted by flow cytometry. Indicated is the MFI of anti-CD20 and HA-2 tetramer staining one week after sorting (upper). As a control, MFI values are shown for a parental HA-2 specific CTL (lower). (C) T cells co-transduced with CD20 and HA-2 TCR (left) and the parental HA-2 specific CTL (right) were compared for RTX-induced CDC. T cells were treated with RTX and BRC or heat inactivated HS for 1 h at 37°C. After CDC, T cells were washed and analyzed for cytolytic activity against HA-2 peptide-pulsed EBV-Z (HLA-A*0201+ HA-2−) and EBV-RZ (HLA-A*0201+ HA-2+) in 51Cr-release assay at E:T ratios of 10:1 as determined prior to CDC.
Similar articles
- The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells.
van Meerten T, Claessen MJ, Hagenbeek A, Ebeling SB. van Meerten T, et al. Gene Ther. 2006 May;13(9):789-97. doi: 10.1038/sj.gt.3302705. Gene Ther. 2006. PMID: 16421601 - Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies.
Introna M, Barbui AM, Bambacioni F, Casati C, Gaipa G, Borleri G, Bernasconi S, Barbui T, Golay J, Biondi A, Rambaldi A. Introna M, et al. Hum Gene Ther. 2000 Mar 1;11(4):611-20. doi: 10.1089/10430340050015798. Hum Gene Ther. 2000. PMID: 10724039 - Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I, Stroopinsky D, Katz T. Avivi I, et al. Blood Rev. 2013 Sep;27(5):217-23. doi: 10.1016/j.blre.2013.07.002. Epub 2013 Aug 13. Blood Rev. 2013. PMID: 23953071 Review. - Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL, Figgitt DP. Plosker GL, et al. Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005. Drugs. 2003. PMID: 12662126 Review.
Cited by
- Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy.
Bangayan NJ, Wang L, Burton Sojo G, Noguchi M, Cheng D, Ta L, Gunn D, Mao Z, Liu S, Yin Q, Riedinger M, Li K, Wu AM, Stoyanova T, Witte ON. Bangayan NJ, et al. Proc Natl Acad Sci U S A. 2023 Nov 21;120(47):e2312374120. doi: 10.1073/pnas.2312374120. Epub 2023 Nov 14. Proc Natl Acad Sci U S A. 2023. PMID: 37963244 Free PMC article. - Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.
Abramson HN. Abramson HN. Int J Mol Sci. 2023 Oct 27;24(21):15674. doi: 10.3390/ijms242115674. Int J Mol Sci. 2023. PMID: 37958658 Free PMC article. Review. - Universal cell donor lines: A review of the current research.
Simpson A, Hewitt AW, Fairfax KA. Simpson A, et al. Stem Cell Reports. 2023 Nov 14;18(11):2038-2046. doi: 10.1016/j.stemcr.2023.09.010. Epub 2023 Oct 12. Stem Cell Reports. 2023. PMID: 37832541 Free PMC article. Review. - Challenges and new technologies in adoptive cell therapy.
Zhang P, Zhang G, Wan X. Zhang P, et al. J Hematol Oncol. 2023 Aug 18;16(1):97. doi: 10.1186/s13045-023-01492-8. J Hematol Oncol. 2023. PMID: 37596653 Free PMC article. Review. - Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
Wang H, Tang L, Kong Y, Liu W, Zhu X, You Y. Wang H, et al. Int J Mol Sci. 2023 May 23;24(11):9115. doi: 10.3390/ijms24119115. Int J Mol Sci. 2023. PMID: 37298069 Free PMC article. Review.
References
- Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719–24. - PubMed
- Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F, et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther. 2007;15:1248–52. - PubMed
- Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2:512–9. - PubMed
- Heemskerk MHM, Hoogeboom M, de Paus RA, Kester MGD, van der Hoorn MAWG, Goulmy E, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood. 2003;102:3530–40. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources